Erlotinib is a highly specific epidermal growth factor receptor tyrosine kinase inhibitor used to treat various metastatic cancers. The most commonly reported side effects in patients receiving erlotinib are dermatitis and diarrhea. The authors present two cases of erlotinib-induced severe scalp perifolliculitis, which is an adverse reaction that has not been reported to date. Both patients developed pustules and thick yellow-green crusted plaques on the scalp within weeks of starting treatment with erlotinib for metastatic non-small cell lung carcinoma. Skin biopsies revealed a perifollicular accumulation of inflammatory cells, lymphocytes, and neutrophils. Both patients were treated with oral doxycycline and achieved complete resolution within 2 to 3 weeks and no recurrence despite continuing the epidermal growth factor receptor tyrosine kinase inhibitor. This is a unique presentation of an erlotinib-induced skin eruption.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Surgery combined with photodynamic therapy for the case of perifolliculitis capitis abscedens et suffodiens: A case report.
SAGE Open Med Case Rep
June 2024
Department of Dermatology, Guiqian International General Hospital, Guiyang, China.
Article Synopsis
- Perifolliculitis capitis abscedens et suffodiens (dissecting cellulitis of the scalp) is a rare, chronic condition that affects hair follicles on the scalp and can significantly impact a person’s quality of life.
- Treatment options are diverse and often challenging to navigate.
- A case study of a 19-year-old male showed positive results from a combination of surgery and photodynamic therapy, particularly for those who did not respond well to traditional treatments.
Effectiveness of 5-aminolevulinic acid photodynamic therapy in treating dissecting cellulitis of the scalp and pathological changes in skin lesions: A retrospective study.
Photodiagnosis Photodyn Ther
August 2024
Department of Dermatology, the Second Affiliated Hospital of Xi 'an Jiaotong University, Xi'an 710000, China. Electronic address:
Article Synopsis
- Dissecting cellulitis of the scalp (DCS) negatively affects patients' physical well-being and body image, and conventional treatments often fail, prompting the exploration of alternative therapies like 5-aminolevulinic acid photodynamic therapy (ALA-PDT).
- The study involved 12 male patients treated with ALA-PDT, with results assessed through symptom scores and photographic comparisons taken before and after the treatment, focusing on pain relief and recurrence rates.
- Results indicated that 75% of patients experienced significant reductions in symptoms, with notable improvements in pain relief, subcutaneous sinus tract symptoms, and alopecia, along with a decrease in inflammatory cells in the lesions.
Single microneedle radiofrequency provides rapid symptom relief in patients with dissecting cellulitis of the scalp: A case report.
J Cosmet Dermatol
September 2024
Department of Dermatology, Hunan Brain Hospital/Second People's Hospital of Human Province, Changsha, China.
Oral abrocitinib in the treatment of refractory dissecting cellulitis of the scalp: A case report.
J Dermatol
October 2024
Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou, China.
Photodynamic therapy combined with carbon dioxide laser pretreatment for treatment of perifolliculitis capitis abscedens et suffodiens: A case report.
Photodiagnosis Photodyn Ther
April 2024
Department of Dermatology, Huadong Hospital, Fudan University, 221 West Yan'an Road, Shanghai 200040, China. Electronic address:
Article Synopsis
- Perifolliculitis capitis abscedens et suffodiens (PCAS) is a tough-to-treat chronic skin condition on the scalp that negatively impacts patients' appearance and quality of life.
- This study discusses a patient with PCAS who underwent a new treatment combining 20% 5-aminolevulinic acid photodynamic therapy (ALA-PDT) and carbon dioxide (CO2) laser pretreatment.
- Remarkably, the patient's skin lesions completely cleared within two months, with no recurrence reported after one year, marking a potential breakthrough treatment for PCAS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!